Lipoprotein lipase (LPL) is a secreted lipase and the key enzyme in clearing triglycerides from circulating lipoproteins. Because elevated plasma triglycerides are an independent risk factor for cardiovascular disease, we seek ways to enhance LPL activity, which will lower plasma triglycerides. LPL activity is downregulated by a family of macromolecular inhibitors known as angiopoietin-like (ANGPTL) proteins. This family includes the LPL inhibitors ANGPTL3, ANGPTL4, and ANGPTL8. Loss-of-function mutations in the ANGPTLs results in increased LPL activity, and decreased serum triglycerides. Our objectives in this study are to better understand how the ANGPTLs associate with LPL, and with each other, so that we can target these interactions to prevent LPL inhibition. We will achieve these objectives in three specific aims.
In Aim 1, we will build on our knowledge of the mechanisms used by ANGPTL3 and ANGPTL4 to inhibit LPL to identify new therapeutics that specifically block the inhibitor-LPL interaction.
In Aim 2, we will use cryo-electron microscopy to solve structures of LPL bound to its inhibitors. Finally, in Aim 3, we will study the function of inhibitors within cells, and their transport out of cells. Successful completion of these aims will provide molecular details describing how LPL and its inhibitors come together, as well as new ways to block these interactions. Because of LPL's key role in regulating plasma triglyceride levels, these discoveries hold promise for new ways to prevent cardiovascular disease.

Public Health Relevance

Approximately one quarter of Americans have elevated plasma triglyceride levels, which are a risk factor for heart disease. We aim to enhance the activity of lipoprotein lipase, the enzyme that clears triglycerides from the blood, by blocking its inhibitors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL125654-06
Application #
9973555
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Liu, Lijuan
Project Start
2015-07-01
Project End
2025-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Biochemistry
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hayne, Cassandra K; Yumerefendi, Hayretin; Cao, Lin et al. (2018) We FRET so You Don't Have To: New Models of the Lipoprotein Lipase Dimer. Biochemistry 57:241-254
Wu, Ming Jing; Wolska, Anna; Roberts, Benjamin S et al. (2018) Coexpression of novel furin-resistant LPL variants with lipase maturation factor 1 enhances LPL secretion and activity. J Lipid Res 59:2456-2465
Hayne, Cassandra K; Lafferty, Michael J; Eglinger, Brian J et al. (2017) Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake. Biochemistry 56:525-533